Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06521567 · ClinicalTrials.gov registry record · Phase 1
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
A Phase 1 study of Melanoma and Hodgkin Lymphoma, sponsored by GlaxoSmithKline.
- Active
- Registry status
- Phase 1
- Development phase
- 83
- Enrollment target
- 20
- Study locations
NCT06521567: Active Phase 1 study of Melanoma and Hodgkin Lymphoma, sponsored by GlaxoSmithKline.
NCT06521567 is a Phase 1 study of Melanoma and Hodgkin Lymphoma that is active but no longer recruiting, run by GlaxoSmithKline. The registered enrollment target is 83 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06521567, a Phase 1 study of Melanoma and Hodgkin Lymphoma, is active but no longer recruiting, sponsored by GlaxoSmithKline.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 83 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this interventional study is to determine the strength of cobolimab and dostarlimab that is most tolerated in children and young adults who have advanced solid tumors. This study also aims: (a) to check if it is safe to use cobolimab and dostarlimab combination in children and young adults, (b) to see how to manage the side effects that may occur, and (c) the effect of this treatment in participants
Conditions Studied
Interventions
- DRUG Dostarlimab
- DRUG Cobolimab
Study Locations (20)
Other
- GSK Investigational Site - Brno
- GSK Investigational Site - Phaha 5
- GSK Investigational Site - Copenhagen
- GSK Investigational Site - Bordeaux
- GSK Investigational Site - Lyon
- GSK Investigational Site - Paris
- GSK Investigational Site - Strasbourg
- GSK Investigational Site - Villejuif
- GSK Investigational Site - Bologna
- GSK Investigational Site - Naples
- GSK Investigational Site - Barcelona
- GSK Investigational Site - Madrid
- GSK Investigational Site - Madrid
- GSK Investigational Site - Valencia
California
- GSK Investigational Site - Los Angeles
Iowa
- GSK Investigational Site - Iowa City
New Jersey
- GSK Investigational Site - Hackensack
Ohio
- GSK Investigational Site - Cincinnati
Rhode Island
- GSK Investigational Site - Providence
Wisconsin
- GSK Investigational Site - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2025-03-06 |
| Est. Completion | 2026-10-13 |
| Phase | Phase 1 |
What the registry record for NCT06521567 still lists
NCT06521567 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 83 participants, a relatively small participant target, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (88% lower).
The record links to 10 conditions, with Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Dostarlimab is the first listed.
NCT06521567 names 20 study sites across 7 states, led by Other, California, Iowa.
Frequently Asked Questions
What is clinical trial NCT06521567 about?
NCT06521567 is a clinical study titled "A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer". The goal of this interventional study is to determine the strength of cobolimab and dostarlimab that is most tolerated in children and young adults who have advanced solid tumors. This study also aims: (a) to check if it is safe to use cobolimab and dostarlimab combination in children and young adul...
What is the current status of trial NCT06521567?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 83 participants. The study started on 2025-03-06. Estimated completion is 2026-10-13.
What conditions does trial NCT06521567 study?
This clinical trial studies the following conditions: Melanoma, Hodgkin Lymphoma, Osteosarcoma, Ependymoma, Hepatocellular Carcinoma (HCC).
What interventions are being tested in trial NCT06521567?
The interventions under investigation include: Dostarlimab (DRUG), Cobolimab (DRUG).
Who is sponsoring clinical trial NCT06521567?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06521567 being conducted?
This trial has 20 study locations across California, Iowa, New Jersey, Ohio, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06521567's enrollment target sits among peer trials
83 125th of 266 higher than 141 of 266 other Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02974647 · 83 participants · Phase 2
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
- NCT03919292 · 83 participants · Phase 1
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
- NCT04626674 · 83 participants · Phase 1
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
- NCT05277168 · 83 participants · Phase 1
A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI